CA2352387A1 - Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement de la toxoplasmose ou de la cryptosporidiose - Google Patents

Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement de la toxoplasmose ou de la cryptosporidiose Download PDF

Info

Publication number
CA2352387A1
CA2352387A1 CA002352387A CA2352387A CA2352387A1 CA 2352387 A1 CA2352387 A1 CA 2352387A1 CA 002352387 A CA002352387 A CA 002352387A CA 2352387 A CA2352387 A CA 2352387A CA 2352387 A1 CA2352387 A1 CA 2352387A1
Authority
CA
Canada
Prior art keywords
compound
formula
optionally substituted
alkyl
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002352387A
Other languages
English (en)
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Patrick T. Prendergast
Krupakar Paul Thadikonda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbor Biosciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2352387A1 publication Critical patent/CA2352387A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation de composés 17-cétostéroïdes (16.alpha.-bromo-isoandrostérone, par exemple), ainsi que des dérivés, des métabolites et des précurseurs desdits composés, et des sels pharmaceutiquement acceptables de l'un quelconque de ces composés (ci-après appelés collectivement "composés de l'invention") pour le traitement ou la prévention de la toxoplasmose ou de la cryptosporidiose chez des patients nécessitant un tel traitement ou une telle prophylaxie. Les composés de la formule (1) peuvent être également utilisés pour améliorer ou diminuer un ou plusieurs symptômes associés à de telles infections.
CA002352387A 1998-11-27 1999-11-24 Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement de la toxoplasmose ou de la cryptosporidiose Abandoned CA2352387A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11012798P 1998-11-27 1998-11-27
US60/110,127 1998-11-27
US12408799P 1999-03-11 1999-03-11
US60/124,087 1999-03-11
US12605699P 1999-03-23 1999-03-23
US60/126,056 1999-11-08
PCT/US1999/028080 WO2000032176A2 (fr) 1998-11-27 1999-11-24 Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement de la toxoplasmose ou de la cryptosporidiose

Publications (1)

Publication Number Publication Date
CA2352387A1 true CA2352387A1 (fr) 2000-06-08

Family

ID=27380789

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002352387A Abandoned CA2352387A1 (fr) 1998-11-27 1999-11-24 Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement de la toxoplasmose ou de la cryptosporidiose

Country Status (4)

Country Link
AP (1) AP2001002167A0 (fr)
AU (1) AU1923500A (fr)
CA (1) CA2352387A1 (fr)
WO (1) WO2000032176A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
DE60045751D1 (de) 1999-09-30 2011-04-28 Harbor Biosciences Inc Therapeutische Behandlung androgenrezeptorbedingter Leiden

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
CN1216470A (zh) * 1996-04-17 1999-05-12 帕特里克·T·普伦德加斯特 脱氢表雄酮组合治疗方法
WO1998047516A1 (fr) * 1997-04-17 1998-10-29 Prendergast Patrick T Therapie combinee mettant en application des 17-cetosteroides et des inhibiteurs d'interleukine, ou interleukine-10 eventuellement avec des inhibiteurs d'interleukine

Also Published As

Publication number Publication date
WO2000032176A2 (fr) 2000-06-08
WO2000032176A3 (fr) 2000-12-07
AU1923500A (en) 2000-06-19
AP2001002167A0 (en) 2001-06-30

Similar Documents

Publication Publication Date Title
US6667299B1 (en) Pharmaceutical compositions and treatment methods
RU2295534C2 (ru) Полугидрат 16 альфа-бромо-3 бета-гидрокси-5 альфа-андростан-17-он, способ его получения, фармацевтические композиции, применение соединений
CA2352205A1 (fr) Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement du virus de l'hepatite c ou autres togavirus
AU2004237812B2 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis
AU2005211675B2 (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
EP1422234A2 (fr) Steroides avec activité d'immunomodulation, surtout le hemihydrat du 16.alpha.-bromoepiandrosterone
CA2352387A1 (fr) Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement de la toxoplasmose ou de la cryptosporidiose
ZA200103845B (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis.
MXPA01005170A (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other togaviruses
MXPA01005166A (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of african and american trypanosomiasis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued